Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery
On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing healthy organs) suggests joint-homing peptides could deliver therapeutics or fusion imaging nanoparticles to specific diseased tissues. Better imaging, lower radiation and precision, targeted dosing could enhance the therapeutic effect of current and future therapeutics and decrease potential systemic toxicity and adverse reactions.
According to the National Library of Medicine (“NLM”), “drug side-effects, or adverse drug reactions (“ADR”), have become a major healthcare concern … serious drug side-effects are estimated to be the fourth leading cause of death in the US, resulting in 100,000 deaths per year.”
An adverse drug reaction is a “response to a drug which is noxious and unintended and which occurs at doses normally used … for prophylaxis, diagnosis or therapy of disease ….” NLM describes various ADR events and effects:
- Adverse events occurring when “desired therapeutic effects can have additional negative consequences,” i.e., blood pressure drugs causing dizziness if blood pressure drops too low, necessitating a “narrow therapeutic window” for appropriate dosing.
- Adverse effects due to a target that “serves multiple purposes in different tissues of the body,” such as chemotherapeutics that kill all fast-growing cells including, for instance, “precursors to immune cells,” thereby suppressing the immune system. “Side effects due to the therapeutic drug target’s presence in multiple cell and tissue types … lead to attempts to develop better-targeted therapeutic agents that more specifically target the desired pathway or site of disease.
- When a drug binds to unintended targets, this refers to off-targets and can produce ADRs and side effects. Off-target effects “are frequently not known or discovered until after observing an adverse event or side effect … in other cases, the specific target responsible for a side effect is not clear.”
Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic process or joint disease. Current treatment for arthritis has side effects that include nausea, vomiting, diarrhea, tinnitus, hair loss, seizures, fever, congestion, unusual lumps or masses and more. OTC arthritis therapeutics, such as common NSAIDs, can produce stomach ulcers, dizziness and indigestion and can have unpredictable results with other medications. Silo’s novel inventions could greatly limit or eliminate these problems.
Silo and UMB are also investigating central nervous system (“CNS”) homing peptides to deliver targeted payloads of psilocybin for treating Multiple Sclerosis (“MS”) and other neuroinflammatory diseases. These peptides are designed to address numerous challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (“CNS”), and can be used as an imaging tool for inflammation of the spinal cord.
Silo CEO Eric Weisblum said, “The ability to deliver conventional and novel therapeutic compounds directly to targeted areas of the body with homing-peptide technology could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed. There is a tremendous need for creative and unique therapeutics for patients suffering from debilitating diseases … ”
Drug delivery systems for the diagnosis and/or therapy of various diseases – Current Neuropharmacology, 2016, Vol. 14, No. 4
For Silo Pharma’s most recent news, click here.
560 Sylvan Avenue, Suite 3160
Englewood Cliffs, NJ 07632
For more information, visit the company’s website at www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.